Overview

PRIME exits® and American Healthcare Capital are proud to be the exclusive representative of a founder-owned, Southwest based, multispecialty wound care and vascular platform who is seeking a qualified strategic or capital partner to support a majority recapitalization and continued growth. The Company operates an outpatient-first model across clinics, in-home wound care, facility-based care, and a newer outpatient vascular lab / OBL. Core services include wound care, vascular medicine / procedures, podiatry, endocrinology and related chronic-care services. A sell-side Quality of Earnings report is available to review post-LOI acceptance.

Investment Highlights

• Scaled regional specialty platform with outpatient, in-home, and facility-based service channels, including a newer vascular lab positioned for ramping procedure volume.

• Differentiated multispecialty model: wound care supported by vascular, podiatry, and endocrinology capabilities.

• Payor-oriented delivery model with commercial and government-payor relationships, case manager channels and referrals from hospitals, post-acute sites, primary care, specialists, and payors.

• Not tissue-bank dependent: current revenue is primarily generated from billable patient encounters and third-party payer reimbursement rather than revenue derived from tissue banks.

• Sell-side QoE available: TTM Mar-26 revenue was approximately $10.4M, adjusted EBITDA was approximately $1.7M, and adjusted EBITDA margin was 16.4%. Revenue was $8.5M in FY23, $10.9M in FY24, and $10.5M in FY25, based solely on the sell-side QoE. The Company is expected to achieve a $2.5 Million EBITDA over the next 12-months.

Growth Opportunity

Embedded growth levers include continued ramp of the newer vascular lab / OBL, increased utilization of newer clinic capacity, expansion of in-home / mobile wound care, additional payor contracting and referral-channel development, DME, pharmacy and infusion-related opportunities, and selective M&A or de novo expansion into podiatry, wound care, or adjacent specialty practices. Operating leverage may improve as recent infrastructure and clinical capacity investments mature.

Market Positioning

The Company serves high-need chronic-care populations with diabetes, vascular disease, obesity-related complications and complex wounds. Its outpatient-first and home/facility-enabled model is designed to reduce reliance on hospital-based wound centers and support payors seeking lower-cost, coordinated care settings.

Transaction Structure

The Founder is seeking a qualified strategic or capital partner and is open to a majority recapitalization, retaining significant equity with the right partner and incorporating an earn-out. The opportunity may be attractive to strategic healthcare organizations, payors, chronic-care platforms, wound care groups, vascular / cardiology platforms, and private equity-backed healthcare services groups.

Asking Price & Valuation

The final valuation shall be determined through discussion and negotiations. The final agreed valuation is expected to be based on a cash-free, debt-free transaction and excludes accounts receivable, personal property, and real property.

Process

Additional information can be made available under NDA to qualified parties. The Sell-Side QE is available only after an accepted LOI.